Buchanan Ingersoll & Rooney represented Cure Penn in the sale of three dispensaries located in Lancaster, Philadelphia and Phoenixville, Pennsylvania to multi-state cannabis operator and wholesaler Cresco Labs in a deal worth roughly $90 million. Cresco Labs will acquire 100% of the equity assets of the three dispensaries. The transaction will be completed on a cash-free, debt-free basis through a cash-and-stock payment. Andrew Giorgione, shareholder in the firm’s Government Relations group and David Monaghan, shareholder in the Corporate section led the Buchanan team. Read more about this transaction in the Law360 article, "3 Firms Guide Cresco Labs' $90M Buy Of Pa. Pot Dispensaries"